Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function.

Nagate Y, Ezoe S, Fujita J, Okuzakis D, Motooka D, Ishibashi T, Ichii M, Tanimura A, Kurashige M, Morii E, Fukushima T, Suehiro Y, Yokota T, Shibayama H, Oritani K, Kanakura Y.

Leukemia. 2020 Mar 20. doi: 10.1038/s41375-020-0788-y. [Epub ahead of print]

PMID:
32203145
2.

Limbic encephalitis with antibodies to N-methyl-D-aspartate (NMDA)-type glutamate receptor after allogeneic transplantation.

Toda J, Maeda T, Akuta K, Kusakabe S, Ueda T, Fujita J, Shibayama H, Oritani K, Takahashi Y, Kanakura Y.

Int J Hematol. 2020 Mar 21. doi: 10.1007/s12185-020-02859-0. [Epub ahead of print]

PMID:
32200528
3.

Enterococcus: A Predictor of Ravaged Microbiota and Poor Prognosis after Allogeneic Hematopoietic Stem Cell Transplantation.

Kusakabe S, Fukushima K, Yokota T, Hino A, Fujita J, Motooka D, Nakamura S, Shibayama H, Kanakura Y.

Biol Blood Marrow Transplant. 2020 Feb 1. pii: S1083-8791(20)30052-5. doi: 10.1016/j.bbmt.2020.01.019. [Epub ahead of print]

PMID:
32018061
4.

Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study.

Takamatsu H, Iida S, Shibayama H, Shibayama K, Yamazaki H, Suzuki K.

Int J Hematol. 2020 Jan 30. doi: 10.1007/s12185-020-02825-w. [Epub ahead of print]

PMID:
32002821
5.

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.

Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, Tanaka H, Shindo M, Kumagai T, Ikezoe T, Uoshima N, Sato T, Watanabe R, Kowata S, Hayakawa M, Hosoki T, Ikeda K, Kobayashi T, Kakinoki Y, Nishimoto T, Takezako N, Shibayama H, Takaori-Kondo A, Nakamae H, Kawaguchi A, Ureshino H, Sakamoto J, Ishida Y; DADI Trial Group.

Lancet Haematol. 2020 Mar;7(3):e218-e225. doi: 10.1016/S2352-3026(19)30235-2. Epub 2020 Jan 21.

PMID:
31978329
6.

Signal-transducing adaptor protein-2 delays recovery of B lineage lymphocytes during hematopoietic stress.

Ichii M, Oritani K, Toda J, Saito H, Shi H, Shibayama H, Motooka D, Kitai Y, Muromoto R, Kashiwakura JI, Saitoh K, Okuzaki D, Matsuda T, Kanakura Y.

Haematologica. 2020 Jan 23. pii: haematol.2019.225573. doi: 10.3324/haematol.2019.225573. [Epub ahead of print]

7.

Unexpected Complication of R-CHOP Chemotherapy: Rapidly Progressive Bronchiolitis Obliterans Syndrome.

Nozaki K, Ezoe S, Hamaguchi M, Tsutsumi K, Kusakabe S, Morikawa Y, Fujita J, Fukushima K, Maeda T, Shibayama H, Kumanogo A, Kanakura Y.

Eur J Case Rep Intern Med. 2019 Oct 28;6(11):001266. doi: 10.12890/2019_001266. eCollection 2019.

8.

Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.

Shibayama H, Teshima T, Choi I, Hatake K, Sekiguchi N, Yoshinari N.

J Clin Exp Hematop. 2019;59(4):179-186. doi: 10.3960/jslrt.19023.

9.

Endothelial Cell-Selective Adhesion Molecule Contributes to the Development of Definitive Hematopoiesis in the Fetal Liver.

Ueda T, Yokota T, Okuzaki D, Uno Y, Mashimo T, Kubota Y, Sudo T, Ishibashi T, Shingai Y, Doi Y, Ozawa T, Nakai R, Tanimura A, Ichii M, Ezoe S, Shibayama H, Oritani K, Kanakura Y.

Stem Cell Reports. 2019 Dec 10;13(6):992-1005. doi: 10.1016/j.stemcr.2019.11.002.

10.

Pre- and post-serial metagenomic analysis of gut microbiota as a prognostic factor in patients undergoing haematopoietic stem cell transplantation.

Kusakabe S, Fukushima K, Maeda T, Motooka D, Nakamura S, Fujita J, Yokota T, Shibayama H, Oritani K, Kanakura Y.

Br J Haematol. 2020 Feb;188(3):438-449. doi: 10.1111/bjh.16205. Epub 2019 Sep 30.

PMID:
31566729
11.

Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.

Miyawaki H, Kioka H, Sato K, Kurashige M, Ozawa T, Shibayama H, Hikoso S, Morii E, Yamauchi-Takihara K, Sakata Y.

Intern Med. 2020 Jan 15;59(2):229-233. doi: 10.2169/internalmedicine.3528-19. Epub 2019 Sep 18.

12.

Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.

Fukuhara N, Yamamoto G, Tsujimura H, Chou T, Shibayama H, Yanai T, Shibuya K, Izutsu K.

Leuk Lymphoma. 2020 Jan;61(1):176-180. doi: 10.1080/10428194.2019.1654100. Epub 2019 Aug 22. No abstract available.

PMID:
31437057
13.

Transcription Factor Sox4 as a Potential Player in Mammary Gland Involution.

Shibayama H, Yamamoto T, Oshima K, Matsuda T, Nadano D.

DNA Cell Biol. 2019 Oct;38(10):1125-1133. doi: 10.1089/dna.2019.4700. Epub 2019 Aug 13.

PMID:
31408364
14.

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study.

Iida S, Watanabe T, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Tobinai K.

Cancer Sci. 2019 Sep;110(9):2924-2932. doi: 10.1111/cas.14139. Epub 2019 Aug 10.

15.

Dissipation-Assisted Coherence Formation in a Spinor Quantum Gas.

Eto Y, Shibayama H, Shibata K, Torii A, Nabeta K, Saito H, Hirano T.

Phys Rev Lett. 2019 Jun 21;122(24):245301. doi: 10.1103/PhysRevLett.122.245301.

PMID:
31322383
16.

Additional validation of Osaka method (0.01 mol/L dithiothreitol) for negating the daratumumab interference.

Hosokawa M, Kashiwagi H, Nakayama K, Sakuragi M, Nakao M, Morikawa T, Kiyokawa T, Aochi H, Nagamine K, Shibayama H, Tomiyama Y.

Transfusion. 2019 Jul;59(7):2479-2480. doi: 10.1111/trf.15305. No abstract available.

PMID:
31268593
17.

Noninvasive assessment of corneal alterations associated with monoclonal gammopathy.

Ichii M, Koh S, Maeno S, Busch C, Oie Y, Maeda T, Shibayama H, Nishida K, Kanakura Y.

Int J Hematol. 2019 Oct;110(4):500-505. doi: 10.1007/s12185-019-02664-4. Epub 2019 May 20.

PMID:
31111396
18.

Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.

Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, Shibayama H, Tomiyama Y, Kanakura Y.

Int J Hematol. 2019 Feb;109(2):197-205. doi: 10.1007/s12185-018-2562-8. Epub 2018 Nov 17.

PMID:
30448938
19.

Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method).

Hosokawa M, Kashiwagi H, Nakayama K, Sakuragi M, Nakao M, Morikawa T, Kiyokawa T, Aochi H, Nagamine K, Shibayama H, Tomiyama Y.

Transfusion. 2018 Dec;58(12):3003-3013. doi: 10.1111/trf.14900. Epub 2018 Sep 28.

PMID:
30267414
20.

STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target.

Onozawa E, Shibayama H, Takada H, Imadome KI, Aoki S, Yoshimori M, Shimizu N, Fujiwara S, Koyama T, Miura O, Arai A.

Oncotarget. 2018 Jul 24;9(57):31077-31089. doi: 10.18632/oncotarget.25780. eCollection 2018 Jul 24.

21.

Correction to: Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.

Maruyama D, Tsukasaki K, Uchida T, Maeda Y, Shibayama H, Nagai H, Kurosawa M, Suehiro Y, Hatake K, Ando K, Yoshida I, Hidaka M, Murayama T, Okitsu Y, Tsukamoto N, Taniwaki M, Suzumiya J, Tamura K, Yamauchi T, Ueda R, Tobinai K.

Ann Hematol. 2018 Dec;97(12):2529-2530. doi: 10.1007/s00277-018-3455-x.

22.

Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry.

Nakaya A, Yagi H, Kaneko H, Kosugi S, Kida T, Adachi Y, Shibayama H, Kohara T, Kamitsuji Y, Fuchida SI, Uoshima N, Kawata E, Uchiyama H, Shimura Y, Takahashi T, Urase F, Ohta K, Hamada T, Miyamoto K, Kobayashi M, Shindo M, Tanaka H, Shimazaki C, Hino M, Kuroda J, Kanakura Y, Takaoari-Kondo A, Nomura S, Matsumura I; Kansai Myeloma Forum Investigators.

Leuk Res Rep. 2018 Jul 4;10:7-10. doi: 10.1016/j.lrr.2018.07.001. eCollection 2018.

23.

Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.

Morita Y, Maeda Y, Yamaguchi T, Urase F, Kawata S, Hanamoto H, Tsubaki K, Ishikawa J, Shibayama H, Matsumura I, Matsuda M.

Cancer Sci. 2018 Oct;109(10):3209-3215. doi: 10.1111/cas.13739. Epub 2018 Aug 26.

24.

Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.

Maruyama D, Tsukasaki K, Uchida T, Maeda Y, Shibayama H, Nagai H, Kurosawa M, Suehiro Y, Hatake K, Ando K, Yoshida I, Hidaka M, Murayama T, Okitsu Y, Tsukamoto N, Taniwaki M, Suzumiya J, Tamura K, Yamauchi T, Ueda R, Tobinai K.

Ann Hematol. 2019 Jan;98(1):131-142. doi: 10.1007/s00277-018-3418-2. Epub 2018 Jul 5. Erratum in: Ann Hematol. 2018 Dec;97(12):2529-2530.

25.

Variable SATB1 Levels Regulate Hematopoietic Stem Cell Heterogeneity with Distinct Lineage Fate.

Doi Y, Yokota T, Satoh Y, Okuzaki D, Tokunaga M, Ishibashi T, Sudo T, Ueda T, Shingai Y, Ichii M, Tanimura A, Ezoe S, Shibayama H, Kohwi-Shigematsu T, Takeda J, Oritani K, Kanakura Y.

Cell Rep. 2018 Jun 12;23(11):3223-3235. doi: 10.1016/j.celrep.2018.05.042.

26.

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.

Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Mizuta S, Hashino S, Nomura T, Shikami M, Fukutani H, Ohe Y, Kosugi H, Shibayama H, Maeda Y, Fukushima T, Yamazaki H, Tsubaki K, Kukita T, Adachi Y, Nataduka T, Sakoda H, Yokoyama H, Okamoto T, Shirasugi Y, Onishi Y, Nohgawa M, Yoshihara S, Morita S, Sakamoto J, Kimura S; DADI Trial Group, Japan.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):353-360.e1. doi: 10.1016/j.clml.2018.03.004. Epub 2018 Mar 15.

27.

[A case of acute leukoencephalopathy induced by a combination of 5-fluorouracil and metronidazole].

Fukumoto T, Katada F, Sato S, Shibayama H, Murayama S, Fukutake T.

Rinsho Shinkeigaku. 2018 Feb 28;58(2):118-123. doi: 10.5692/clinicalneurol.cn-001105. Epub 2018 Jan 31. Japanese.

PMID:
29386497
28.

Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.

Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A; Kansai Myeloma Forum Investigators.

Int J Hematol. 2018 May;107(5):541-550. doi: 10.1007/s12185-018-2416-4. Epub 2018 Jan 29.

PMID:
29380179
29.

Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).

Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka KI, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y.

Int J Hematol. 2018 May;107(5):535-540. doi: 10.1007/s12185-018-2401-y. Epub 2018 Jan 23.

PMID:
29362980
30.

Clinical and mutational spectrum of Japanese patients with recessive variants in SH3TC2.

Yuan JH, Hashiguchi A, Okamoto Y, Yoshimura A, Ando M, Shiomi K, Saito K, Takahashi M, Ichinose K, Ohmichi T, Ichikawa K, Tadashi A, Takigawa H, Shibayama H, Takashima H.

J Hum Genet. 2018 Mar;63(3):281-287. doi: 10.1038/s10038-017-0388-5. Epub 2018 Jan 10.

PMID:
29321516
31.

Identification of MS4A3 as a reliable marker for early myeloid differentiation in human hematopoiesis.

Ishibashi T, Yokota T, Satoh Y, Ichii M, Sudo T, Doi Y, Ueda T, Nagate Y, Hamanaka Y, Tanimura A, Ezoe S, Shibayama H, Oritani K, Kanakura Y.

Biochem Biophys Res Commun. 2018 Jan 15;495(3):2338-2343. doi: 10.1016/j.bbrc.2017.12.117. Epub 2017 Dec 22.

PMID:
29274779
32.

Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.

Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H.

Int J Hematol. 2018 Mar;107(3):327-336. doi: 10.1007/s12185-017-2353-7. Epub 2017 Oct 26.

PMID:
29076005
33.

[A case of primary central nervous system anaplastic lymphoma kinase positive anaplastic large cell lymphoma manifested as a unilateral pachymeningits].

Fujisawa E, Shibayama H, Mitobe F, Katada F, Sato S, Fukutake T.

Rinsho Shinkeigaku. 2017 Nov 25;57(11):705-710. doi: 10.5692/clinicalneurol.cn-001030. Epub 2017 Oct 26. Review. Japanese.

PMID:
29070753
34.

Correction: EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.

Takada H, Imadome KI, Shibayama H, Yoshimori M, Wang L, Saitoh Y, Uota S, Yamaoka S, Koyama T, Shimizu N, Yamamoto K, Fujiwara S, Miura O, Arai A.

PLoS One. 2017 Aug 1;12(8):e0182682. doi: 10.1371/journal.pone.0182682. eCollection 2017.

35.

Virus-specific cytotoxic T cells in chronic active Epstein-Barr virus infection.

Shibayama H, Imadome KI, Onozawa E, Tsuzura A, Miura O, Koyama T, Arai A.

Rinsho Ketsueki. 2017;58(6):583-588. doi: 10.11406/rinketsu.58.583. Japanese.

PMID:
28679986
36.

The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis.

Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Takahashi H, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Nakajima H, Miura I, Takeuchi K.

Leuk Lymphoma. 2018 Jan;59(1):97-104. doi: 10.1080/10428194.2017.1330541. Epub 2017 Jun 8.

PMID:
28593796
37.

Inflammatory cytokine production in chronic active Epstein-Barr virus infection.

Onozawa E, Shibayama H, Imadome KI, Tsuzura A, Koyama T, Miura O, Arai A.

Rinsho Ketsueki. 2017;58(3):189-196. doi: 10.11406/rinketsu.58.189. Japanese.

PMID:
28381684
38.

EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.

Takada H, Imadome KI, Shibayama H, Yoshimori M, Wang L, Saitoh Y, Uota S, Yamaoka S, Koyama T, Shimizu N, Yamamoto K, Fujiwara S, Miura O, Arai A.

PLoS One. 2017 Mar 27;12(3):e0174136. doi: 10.1371/journal.pone.0174136. eCollection 2017. Erratum in: PLoS One. 2017 Aug 1;12 (8):e0182682.

39.

Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88L265P mutation.

Kida T, Tanimura A, Ono A, Matsui T, Honma K, Fujita J, Maeda T, Shibayama H, Oritani K, Morii E, Kanakura Y.

Rinsho Ketsueki. 2017;58(2):155-160. doi: 10.11406/rinketsu.58.155. Japanese.

PMID:
28321094
40.

Identification of novel SNORD118 mutations in seven patients with leukoencephalopathy with brain calcifications and cysts.

Iwama K, Mizuguchi T, Takanashi JI, Shibayama H, Shichiji M, Ito S, Oguni H, Yamamoto T, Sekine A, Nagamine S, Ikeda Y, Nishida H, Kumada S, Yoshida T, Awaya T, Tanaka R, Chikuchi R, Niwa H, Oka YI, Miyatake S, Nakashima M, Takata A, Miyake N, Ito S, Saitsu H, Matsumoto N.

Clin Genet. 2017 Aug;92(2):180-187. doi: 10.1111/cge.12991. Epub 2017 Mar 30.

PMID:
28177126
41.

Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102).

Ogiya D, Shibayama H, Nakatani E, Ando K, Suzuki K, Kuroda Y, Uchida T, Maruyama D, Matsumoto M, Matsue K, Iida S, Terui Y, Ri M, Chou T, Aotsuka N, Tabata S, Konishi J, Ohashi K, Shinagawa A, Sugiura I, Kuroda J, Miyamoto T, Ogura M, Tobinai K, Kanakura Y, Hotta T.

Rinsho Ketsueki. 2016;57(11):2311-2318. Japanese.

PMID:
27941278
42.

Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.

Takenaka K, Shimoda K, Uchida N, Shimomura T, Nagafuji K, Kondo T, Shibayama H, Mori T, Usuki K, Azuma T, Tsutsumi Y, Tanaka J, Dairaku H, Matsuo K, Ozawa K, Kurokawa M, Arai S, Akashi K.

Int J Hematol. 2017 Jan;105(1):59-69. doi: 10.1007/s12185-016-2102-3. Epub 2016 Oct 19.

PMID:
27761702
43.

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.

Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Shibayama H, Choi I, Hatake K, Uchida T, Nishikori M, Kinoshita T, Matsuno Y, Nishikawa T, Takahara S, Tobinai K.

Cancer Sci. 2016 Dec;107(12):1785-1790. doi: 10.1111/cas.13076. Epub 2016 Nov 25.

44.

Second primary malignancies among patients with myeloma-related-diseases in the KMF database.

Kosugi S, Shibayama H, Nakatani E, Kida T, Ohta K, Kaneko H, Yagi H, Tanaka H, Fuchida S, Nakaya A, Kobayashi M, Kuroda J, Kamitsuji Y, Uoshima N, Adachi Y, Tsudo M, Shimazaki C, Nomura S, Hino M, Matsumura I, Taniwaki M, Kanakura Y, Takaori-Kondo A.

Rinsho Ketsueki. 2016 Jul;57(7):839-47. doi: 10.11406/rinketsu.57.839. Japanese.

PMID:
27498726
45.

[Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: VIII. Novel Drugs for Multiple Myeloma].

Shibayama H.

Nihon Naika Gakkai Zasshi. 2016 Jul;105(7):1255-60. Japanese. No abstract available.

PMID:
30168970
46.

Optimization of the alkyl side chain length of fluorine-18-labeled 7α-alkyl-fluoroestradiol.

Okamoto M, Shibayama H, Naka K, Kitagawa Y, Ishiwata K, Shimizu I, Toyohara J.

Nucl Med Biol. 2016 Aug;43(8):512-9. doi: 10.1016/j.nucmedbio.2016.05.008. Epub 2016 May 28.

PMID:
27289329
47.

New variant of acute promyelocytic leukemia with IRF2BP2-RARA fusion.

Shimomura Y, Mitsui H, Yamashita Y, Kamae T, Kanai A, Matsui H, Ishibashi T, Tanimura A, Shibayama H, Oritani K, Kuyama J, Kanakura Y.

Cancer Sci. 2016 Aug;107(8):1165-8. doi: 10.1111/cas.12970.

48.

Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.

Kobayashi S, Ueda Y, Nannya Y, Shibayama H, Tamura H, Ogata K, Akatsuka Y, Usuki K, Ito Y, Okada M, Suzuki T, Hata T, Matsuda A, Tohyama K, Kakumoto K, Koga D, Mitani K, Naoe T, Sugiyama H, Takaku F.

Cancer Biomark. 2016 Mar 31;17(1):21-32. doi: 10.3233/CBM-160612.

PMID:
27062571
49.

ESAM is a novel human hematopoietic stem cell marker associated with a subset of human leukemias.

Ishibashi T, Yokota T, Tanaka H, Ichii M, Sudo T, Satoh Y, Doi Y, Ueda T, Tanimura A, Hamanaka Y, Ezoe S, Shibayama H, Oritani K, Kanakura Y.

Exp Hematol. 2016 Apr;44(4):269-81.e1. doi: 10.1016/j.exphem.2015.12.010. Epub 2016 Jan 14.

PMID:
26774386
50.

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.

Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S.

Br J Haematol. 2016 Mar;172(5):745-56. doi: 10.1111/bjh.13900. Epub 2016 Jan 5.

Supplemental Content

Loading ...
Support Center